Thermo Fisher Scientific Inc. (NYSE:TMO) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Shares of Thermo Fisher Scientific Inc. (NYSE:TMOGet Free Report) have been given an average recommendation of “Moderate Buy” by the eighteen brokerages that are presently covering the firm, MarketBeat.com reports. Five investment analysts have rated the stock with a hold recommendation and thirteen have assigned a buy recommendation to the company. The average 12-month price objective among brokerages that have issued a report on the stock in the last year is $606.47.

A number of research analysts have issued reports on TMO shares. HSBC upped their price target on shares of Thermo Fisher Scientific from $660.00 to $670.00 and gave the company a “buy” rating in a research note on Tuesday, April 30th. Robert W. Baird cut their price objective on shares of Thermo Fisher Scientific from $621.00 to $620.00 and set an “outperform” rating on the stock in a research note on Thursday, April 25th. Citigroup initiated coverage on shares of Thermo Fisher Scientific in a research note on Monday, March 18th. They issued a “neutral” rating and a $620.00 price objective on the stock. JPMorgan Chase & Co. increased their price objective on shares of Thermo Fisher Scientific from $600.00 to $650.00 and gave the stock an “overweight” rating in a research note on Thursday, April 25th. Finally, Deutsche Bank Aktiengesellschaft raised their price target on shares of Thermo Fisher Scientific from $600.00 to $610.00 and gave the company a “buy” rating in a research report on Thursday, April 25th.

Get Our Latest Stock Report on TMO

Insider Activity at Thermo Fisher Scientific

In related news, CEO Marc N. Casper sold 10,000 shares of Thermo Fisher Scientific stock in a transaction that occurred on Tuesday, April 30th. The shares were sold at an average price of $572.41, for a total value of $5,724,100.00. Following the completion of the transaction, the chief executive officer now owns 123,816 shares in the company, valued at $70,873,516.56. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other Thermo Fisher Scientific news, SVP Michael A. Boxer sold 2,000 shares of the business’s stock in a transaction on Friday, April 26th. The shares were sold at an average price of $567.94, for a total value of $1,135,880.00. Following the transaction, the senior vice president now directly owns 13,083 shares of the company’s stock, valued at approximately $7,430,359.02. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Marc N. Casper sold 10,000 shares of the business’s stock in a transaction on Tuesday, April 30th. The shares were sold at an average price of $572.41, for a total transaction of $5,724,100.00. Following the completion of the transaction, the chief executive officer now directly owns 123,816 shares in the company, valued at $70,873,516.56. The disclosure for this sale can be found here. Over the last quarter, insiders sold 22,000 shares of company stock worth $12,532,780. Corporate insiders own 0.34% of the company’s stock.

Hedge Funds Weigh In On Thermo Fisher Scientific

Several institutional investors have recently bought and sold shares of the company. Csenge Advisory Group grew its stake in shares of Thermo Fisher Scientific by 5.5% during the 2nd quarter. Csenge Advisory Group now owns 3,740 shares of the medical research company’s stock worth $2,068,000 after purchasing an additional 194 shares during the period. Legacy Financial Strategies LLC acquired a new position in shares of Thermo Fisher Scientific during the 2nd quarter worth $201,000. Valeo Financial Advisors LLC boosted its position in shares of Thermo Fisher Scientific by 2.7% in the 2nd quarter. Valeo Financial Advisors LLC now owns 4,150 shares of the medical research company’s stock worth $2,295,000 after buying an additional 111 shares in the last quarter. Northside Capital Management LLC boosted its position in shares of Thermo Fisher Scientific by 4.4% in the 2nd quarter. Northside Capital Management LLC now owns 477 shares of the medical research company’s stock worth $264,000 after buying an additional 20 shares in the last quarter. Finally, Aprio Wealth Management LLC boosted its position in shares of Thermo Fisher Scientific by 57.8% in the 2nd quarter. Aprio Wealth Management LLC now owns 792 shares of the medical research company’s stock worth $438,000 after buying an additional 290 shares in the last quarter. 89.23% of the stock is owned by institutional investors and hedge funds.

Thermo Fisher Scientific Trading Up 0.9 %

NYSE:TMO opened at $536.87 on Thursday. Thermo Fisher Scientific has a 52 week low of $415.60 and a 52 week high of $603.82. The firm has a 50 day moving average of $569.33 and a 200 day moving average of $563.82. The company has a quick ratio of 1.33, a current ratio of 1.70 and a debt-to-equity ratio of 0.68. The stock has a market capitalization of $204.93 billion, a price-to-earnings ratio of 34.44, a PEG ratio of 2.50 and a beta of 0.77.

Thermo Fisher Scientific (NYSE:TMOGet Free Report) last posted its earnings results on Wednesday, April 24th. The medical research company reported $5.11 EPS for the quarter, beating analysts’ consensus estimates of $4.70 by $0.41. Thermo Fisher Scientific had a net margin of 14.20% and a return on equity of 18.45%. The company had revenue of $10.35 billion during the quarter, compared to analysts’ expectations of $10.14 billion. As a group, sell-side analysts anticipate that Thermo Fisher Scientific will post 21.65 earnings per share for the current fiscal year.

Thermo Fisher Scientific Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, July 15th. Investors of record on Friday, June 14th will be issued a $0.39 dividend. This represents a $1.56 dividend on an annualized basis and a dividend yield of 0.29%. The ex-dividend date of this dividend is Friday, June 14th. Thermo Fisher Scientific’s dividend payout ratio (DPR) is currently 10.01%.

Thermo Fisher Scientific Company Profile

(Get Free Report

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.

Recommended Stories

Analyst Recommendations for Thermo Fisher Scientific (NYSE:TMO)

Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.